Merz Aesthetics Celebrates 15 Years of XEOMIN® (incobotulinumtoxinA) in the U.S. with One Year of Free Treatments Sweepstakes & New Campaign
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, celebrates 15 years since its flagship brand XEOMIN® was first approved for aesthetic use by the U.S. Food and Drug Administration (FDA). XEOMIN® is adouble-purifiedneurotoxin, FDA approved for the simultaneous treatment of upper facial lines – forehead lines, frown lines and crow’s feet. To celebrate this 15-year U.S. milestone, 15 lucky winners will receive a year of free XEOMIN® treatments through Xperience+ by Merz Aesthetics U.S. patient loyalty program.
In addition, Merz Aesthetics is also launching a new, refreshed campaign for XEOMIN® in celebration of the milestone. The new multi-channel initiative—spanning digital platforms to in-office touchpoints—aims to empower patients to ask for XEOMIN® by showcasing XEOMIN®’s natural-looking results that allow people to express themselves.
Containing only three ingredients, XEOMIN® is the first and only double-purified treatment with XTRACT Technology®, clinically proven to smooth upper facial lines for natural-looking results1. XEOMIN® has a 96% patient satisfaction rate2,3 and a clinically proven track record of delivering safe, effective, and consistent results.2,4,5
“Since its debut, XEOMIN® has been a trusted choice for patients and providers seeking effective, natural-looking results,” said Patrick Urban, President, North America, Merz Aesthetics. “Celebrating 15 years is more than a milestone—it’s a testament to our unwavering commitment to proven performance and advancing aesthetic care.”
With XEOMIN®, no patients in pivotal clinical studies developed treatment resistance due to neutralizing antibodies. In fact, unnecessary proteins found in some other toxin formulations on the U.S. market may cause an immune response which can lead to a decreased effect and failure of treatment.6 In a recent survey, just over 1 in 3 toxin users reported to have experienced decreased, or lessening effects, of toxin treatments.7 XEOMIN®’s formulation minimizes this risk and offers a consistent experience, treatment after treatment.
“Leveraging our proprietary XTRACT Technology® manufacturing process, we have established ourselves as a pioneer in neurotoxins, delivering outcomes and efficacy that both patients and providers expect,” said Dr. Samantha Kerr, Chief Scientific Officer, Merz Aesthetics. “We’re committed to driving continued innovation for years to come.”
To celebrate this U.S. milestone, XEOMIN® is giving 15 lucky U.S. patients the opportunity to win a free year of XEOMIN® treatments through Xperience+ by Merz Aesthetics with a participating Xperience+ provider. From February 11 to March 11, 2026, patients are invited to enter HERE and create an account or login to Xperience+ at xperiencemerz.com. No purchase necessary. Full terms and conditions are included in the entry form.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy.
Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics®’ global headquarters is in Raleigh, N.C., with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany.
About XEOMIN®(incobotulinumtoxinA)
XEOMIN® (incobotulinumtoxinA) is a botulinum toxin type A approved by the U.S. Food and Drug Administration (FDA) for the simultaneous treatment of upper facial lines – forehead lines, frown lines and crow’s feet. XEOMIN® is indicated to temporarily improve the look of moderate to severe upper facial lines.
Source link: https://www.businesswire.com/
